Ionis, Biogen expand partnership for antisense therapies

Biogen Inc. (NASDAQ:BIIB) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) expanded their existing partnership to develop antisense therapies for a range of disease areas including dementia and neurological disease in a 10-year collaboration.

Ionis

Read the full 318 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE